Voriconazole: Nursing Drug Guide, Visual Changes & Hepatotoxicity
Healthcare medication guide: catching transient versus dangerous visual changes, weekly liver monitoring, IV infusion rate limits, and renal route restrictions before voriconazole harms vision, liver function, or kidneys in immunocompromised and ICU patients.
Voriconazole commonly causes visual disturbances and can produce serious hepatic injury, infusion-related anaphylactoid reactions, and QT prolongation when electrolytes are low. IV therapy accumulates SBECD in renal impairment—verify weekly LFTs, visual checks, infusion rate, and route when creatinine clearance is below 50 mL/min.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Obtain baseline LFTs and repeat at least weekly in the first month. Teach patients to report blurred vision, halos, and photophobia immediately. Never bolus IV voriconazole; stop the infusion for chest tightness or flushing. Switch to oral therapy when CrCl is below 50 mL/min unless prescriber and pharmacy document IV benefit/risk.
Most common brand names
Voriconazole is widely dispensed as VFEND tablets, oral suspension, and IV lyophilized powder per institution formulary.
Generic voriconazole and VFEND are single-entity products. Verify formulation (50 mg vs 200 mg tablets, suspension mL dose, or IV vial) and distinguish from fluconazole or other azoles on the MAR.
Why we give it — Indications
Voriconazole treats invasive fungal infections in adults and pediatric patients aged 2 years and older per FDA-approved labeling, including invasive aspergillosis and selected Candida and mold infections.
| Use | Detail |
|---|---|
| Invasive aspergillosis | Primary labeled indication; weight-based IV loading then maintenance; oral step-down when clinically stable and tolerating oral therapy. |
| Candidemia, deep Candida infections, esophageal candidiasis, and refractory Scedosporium/Fusarium | Regimens vary by infection (see dosing table); esophageal candidiasis uses 200 mg orally every 12 hours without evaluated IV loading per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Voriconazole inhibits fungal cytochrome P450-mediated 14-α-demethylase, disrupting ergosterol synthesis. It is metabolized by CYP2C19, CYP2C9, and CYP3A4 and also inhibits these enzymes, producing many clinically significant drug interactions. Non-linear pharmacokinetics mean small dose changes can markedly alter exposure.
Dosing overview
Start with the labeled loading regimen when indicated, then maintenance. Oral 200 mg every 12 hours approximates 3 mg/kg IV every 12 hours; 300 mg orally approximates 4 mg/kg IV per labeling.
Missed dose: If a dose is missed, give it when remembered unless near the next dose; do not double doses. Contact prescriber/pharmacy for prolonged missed doses in life-threatening fungal infection.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Loading regimen | IV 6 mg/kg every 12 hours for first 24 hours (adults); then maintenance | Verify weight-based loading completed before maintenance doses—do not skip or duplicate loading per MAR |
| Oral bioavailability | 200 mg PO every 12 hours ≈ 3 mg/kg IV every 12 hours; 300 mg PO ≈ 4 mg/kg IV | Switch oral/IV only when patient can tolerate oral therapy and prescriber orders route change |
| Steady state | Non-linear pharmacokinetics; exposure rises greater than proportionally with dose | Dose increases require prescriber/pharmacy calculation—never double maintenance without order |
| Half-life | Not specified in the reviewed prescribing information as a single value for all patients | Elderly patients may have higher plasma concentrations—monitor toxicity even without dose change |
| Elimination / dialysis | Voriconazole and IV vehicle SBECD are hemodialyzed (clearance 121 and 55 mL/min respectively in overdose section) | IV route avoided when CrCl <50 mL/min due to SBECD accumulation; trend creatinine on IV therapy |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Azole allergy history and prior infusion reactions to voriconazole
- Weight, baseline LFTs, creatinine/CrCl, and electrolytes (K+, Mg2+, Ca2+)
- Contraindicated/interacting drugs (rifampin, carbamazepine, sirolimus, pimozide, quinidine, ritonavir, St. John’s wort, ergot alkaloids) and QT-risk combinations
Contraindications
- Hypersensitivity to voriconazole or excipients
- Coadministration with pimozide, quinidine, ivabradine, or sirolimus
- Coadministration with rifampin, carbamazepine, long-acting barbiturates, St. John’s wort, high-dose ritonavir, rifabutin, ergot alkaloids, naloxegol, tolvaptan, lurasidone, and selected venetoclax phases per labeling
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Phenytoin or efavirenz | Phenytoin/efavirenz lower voriconazole levels; voriconazole raises phenytoin/efavirenz exposure | Prescriber must increase voriconazole maintenance dose and monitor phenytoin levels/toxicity per labeling |
| Rifampin, carbamazepine, St. John’s wort | Markedly reduced voriconazole concentrations — loss of efficacy | Contraindicated; notify prescriber/pharmacist if ordered together |
| QT-prolonging agents and uncorrected hypokalemia | Additive QT prolongation; rare torsade de pointes reported | Correct electrolytes before therapy; ECG monitoring per orders; avoid prohibited combinations |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet or suspension (empty stomach timing); IV infusion after reconstitution and dilution
- Oral: at least 1 hour before or after meals; shake suspension well before each dose; follow safe medication administration checks
- IV: dilute to ≤5 mg/mL; infuse over 1–3 hours at max 3 mg/kg/hour; never bolus
- Do not infuse IV voriconazole with blood products or concentrated electrolytes—even in separate lines
Stop the infusion immediately for flushing, chest tightness, dyspnea, or rash during IV administration. Document visual symptoms at each shift when therapy continues beyond the first week. Obtain LFTs at initiation and at least weekly for the first month per labeling.
Expected therapeutic response
- Defervescence and clinical stabilization in invasive fungal infection per prescriber targets (may take weeks)
- Improving culture or imaging markers for aspergillosis or candidemia when monitored
- Brief transient visual changes may occur early without indicating treatment failure—trend symptoms
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Visual disturbances (blurred vision, altered color perception, photophobia) | Very common in adults (≈19% in trials); often transient early in therapy | Document onset and duration; teach night-driving caution; notify prescriber if symptoms persist beyond 28 days or suggest optic neuritis |
| Hepatotoxicity (transaminase rise, hepatitis, cholestasis, fulminant failure) | Uncommon but serious; fatalities reported, often in hematologic malignancy | Weekly LFTs first month per labeling; hold and notify prescriber for marked elevations or clinical hepatitis |
| Infusion-related reactions (flushing, fever, chest tightness, rash) | Uncommon with IV formulation; may occur immediately on infusion start | Stop infusion; monitor airway and vitals; follow facility anaphylaxis protocol |
| QT prolongation / arrhythmias | Rare post-marketing torsade de pointes and sudden death with confounding factors | Correct potassium, magnesium, and calcium before and during therapy; monitor ECG when ordered |
| Photosensitivity / severe cutaneous reactions | Photosensitivity reported; SJS, TEN, and DRESS are life-threatening | Teach sun protection; stop drug for progressive rash or mucosal involvement |
| Hallucinations | ≈2.4% in adult trials | Assess mental status; differentiate from hypoxia or sepsis; notify prescriber for new or worsening symptoms |
| Renal toxicity / acute renal failure | Observed in treated patients, often with other nephrotoxins | Trend creatinine; prefer oral route when CrCl <50 mL/min per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Clinical trials reported three accidental overdoses in pediatric patients who received up to five times the recommended IV dose; one adverse reaction of photophobia lasting 10 minutes was reported. Management is supportive. Hemodialysis may assist removal of voriconazole and SBECD in overdose.
Nursing actions
- Stop further doses and notify prescriber/pharmacist and local poison control or toxicology services per facility protocol
- Monitor visual symptoms, liver function, cardiac rhythm, and renal function
- Prepare for hemodialysis discussion when severe toxicity and renal failure coexist per medical team
Contact local poison control or medical toxicology services for guidance on large ingestions or serious visual, hepatic, or cardiac toxicity.
Antidote: No known antidote to voriconazole per prescribing information — treatment is supportive.
Look-alike / sound-alike and error prevention
- Voriconazole vs fluconazole vs itraconazole — verify generic name, dose, and frequency; voriconazole uses weight-based IV loading and twice-daily maintenance unlike many fluconazole regimens
- VFEND vs other “V” antifungals — read vial and MAR aloud; oral suspension must be shaken and measured in millilitres (5 mL = 200 mg when reconstituted per label)
- IV voriconazole vs IV fluconazole — voriconazole requires dilution to ≤5 mg/mL, infusion over 1–3 hours, max 3 mg/kg/hour; never bolus
- 200 mg tablet vs 200 mg/5 mL suspension — confirm formulation on MAR; tablets contain lactose; suspension contains sucrose
- Loading vs maintenance dose — 6 mg/kg q12h × 24 h then 4 mg/kg q12h (IA) is a common error point; pharmacy should verify weight-based entries
- Perform medication reconciliation at admission and transfer to catch duplicate azoles or contraindicated interacting drugs (rifampin, sirolimus, QT agents)
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Before first dose | Reconcile allergies, weight, LFTs, creatinine/CrCl, potassium/magnesium/calcium, QT-risk drugs, pregnancy status, and photosensitivity teaching needs |
| Oral administration | Give tablets or suspension at least 1 hour before or after meals; shake suspension well before each dose |
| IV administration | Infuse over 1–3 hours, max 3 mg/kg/hour; separate line from blood products and concentrated electrolytes |
| Renal impairment | Avoid IV when CrCl <50 mL/min; use oral route and monitor creatinine unless prescriber documents IV benefit/risk |
| Hepatic impairment | Halve maintenance dose in mild–moderate cirrhosis (Child-Pugh A/B); use loading dose then reduced maintenance per labeling |
| Ask pharmacy when | Unclear weight-based dose, phenytoin or efavirenz co-therapy, route switch oral↔IV, rising LFTs, or CrCl falling on IV therapy |
On a small screen, swipe or scroll sideways to see the full table.
Red flags — Stop and act
Stop voriconazole and escalate when life-threatening toxicity or administration errors occur.
- Immediate infusion-related symptoms (chest tightness, flush, dyspnea, hypotension) during IV dose
- Jaundice, dark urine, right upper quadrant pain, or transaminases markedly above baseline
- Persistent visual loss, halos, or color distortion beyond early transient phase—or papilledema signs
- Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS (severe rash with fever and systemic involvement)
- Palpitations, syncope, confusion, or documented torsade de pointes / QTc greater than 500 ms with symptoms
High-risk populations
| Population | Considerations |
|---|---|
| Hematologic malignancy / stem cell transplant recipients | Higher hepatotoxicity and drug interaction burden—intensive LFT and interaction monitoring |
| Renal impairment receiving IV formulation | SBECD accumulation increases renal risk—prefer oral route when CrCl below 50 mL/min |
| Patients on phenytoin, sirolimus, cyclosporine, or corticosteroids | Voriconazole is a potent CYP inhibitor/substrate—levels of both voriconazole and partner drugs may become toxic or subtherapeutic |
| Pregnancy | Can cause fetal harm; no adequate human data. Animal studies showed malformations and fetal toxicity. Use effective contraception during therapy. Reserve for severe life-threatening fungal infections when benefit outweighs fetal risk per prescriber. |
| Lactation | No data on presence in human milk or infant effects. Balance maternal clinical need against potential infant exposure; consider alternative feeding plans per prescriber and lactation specialist when available. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- LFTs and bilirubin at baseline, weekly first month, then monthly if stable per labeling
- Visual symptoms; formal visual function if treatment continues beyond 28 days
- Serum creatinine, electrolytes on basic metabolic panel, and electrocardiogram/QTc when QT-risk drugs or arrhythmia history present
Document
- Weight-based IV dose verification, loading completion, route, and infusion rate
- Visual symptom checks, photosensitivity teaching, and infusion reaction observations
- Hold events, LFT trends, CrCl and route changes, and pharmacy interaction alerts
Patient teaching
- Report blurred vision, halos, color changes, or photophobia—avoid driving at night if vision is affected
- Avoid direct sunlight; use protective clothing and high-SPF sunscreen because photosensitivity and skin malignancy risk increase with long therapy
- Take oral voriconazole 1 hour before or after food; shake liquid suspension well every time
- Tell clinicians about all medicines including herbal products (St. John’s wort is contraindicated)
- Use effective contraception during treatment if of reproductive potential; report pregnancy promptly
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Hypersensitivity, anaphylactoid infusion reaction, or severe cutaneous adverse reaction
- Transaminases markedly elevated compared with baseline or clinical hepatitis/jaundice pending prescriber review
- Persistent or worsening visual symptoms, especially beyond 28 days, until ophthalmology/prescriber review
- IV order when creatinine clearance is below 50 mL/min without documented benefit/risk approval
- Symptomatic severe QT prolongation or torsade de pointes until cardiology/prescriber review
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Safe voriconazole therapy depends on weight-based dose verification, weekly hepatic surveillance, visual checks, and renal-aware route selection from the first IV loading dose.
1. Check-before-you-give protocol
- Confirm weight, loading-dose completion, and maintenance dose match indication (IA vs esophageal candidiasis)
- Verify CrCl supports IV route; prefer oral when below 50 mL/min unless prescriber documents exception
- Review latest LFTs, potassium, magnesium, and interaction alerts (phenytoin, immunosuppressants, QT drugs)
- Ask about new visual symptoms, rash, or photosensitivity before each administration
2. High-alert and safety badge
Vision / hepatic / IV infusion riskVoriconazole is not a traditional high-alert list drug, but visual toxicity, serious hepatic injury, narrow infusion parameters, and major CYP interactions require the same disciplined verification as high-alert therapies in immunocompromised patients.
3. Clinical workflow: hold and question rules
- Stop IV infusion immediately for infusion-related symptoms; do not restart without prescriber/pharmacy plan
- Hold for marked LFT rise or clinical jaundice pending prescriber and hepatology review
- Do not give IV maintenance when CrCl below 50 mL/min without documented exception—request oral route
4. Critical teach-back questions
- “What vision changes should you report while taking voriconazole?” Blurred vision, halos, color changes, photophobia, or any vision loss—especially if persistent.
- “Why must you avoid sun exposure during voriconazole therapy?” Because the drug causes photosensitivity and long-term skin damage including skin cancer risk per labeling.
5. Care coordination
Pharmacist: Weight-based dosing, interaction screening (phenytoin, sirolimus, rifampin), route selection for renal function, and TDM when ordered
Infectious diseases / primary prescriber: Culture and imaging response, duration of therapy, oral step-down, and antifungal switch when toxicity or resistance occurs
🧠 Quick mental checklist
- Was loading dose completed and does maintenance match weight and indication?
- Is IV route appropriate for today’s creatinine clearance?
- What are today’s LFTs, potassium, and visual symptom status?
- Are contraindicated inducers or QT drugs on the MAR?
- Has pharmacy signed off phenytoin or immunosuppressant interactions?
Voriconazole NCLEX practice questions
Practice NCLEX-style clinical judgment practice for voriconazole using a tabbed case (MAR, labs, vitals/history, nursing notes) focused on visual changes, hepatotoxicity, and IV infusion safety—then work through priority action, cue recognition, trend interpretation, matrix urgency, renal route rules, and documentation cloze: recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, Vitals / History, and nursing note details for this case.
- Voriconazole 200 mg PO q12h — day 8 invasive aspergillosis (switched from IV day 6)
- Phenytoin 300 mg PO daily — therapeutic drug monitoring due
- Prednisone 40 mg PO daily — post-transplant immunosuppression
- Potassium chloride 40 mEq PO daily — ordered for hypokalemia
- AST 42 → 128 → 186 U/L (72 h trend); ALT 38 → 142 U/L
- Potassium 3.0 mEq/L; magnesium 1.5 mg/dL
- Creatinine 1.8 mg/dL; eGFR 42 mL/min (was 58 mL/min on admission)
- Total bilirubin 1.1 mg/dL (stable)
- BP 104/68; HR 96; temp 37.4 °C
- ECG: QTc 468 ms (prior 432 ms)
- Weight 52 kg; hematologic malignancy with recent stem cell transplant
- Patient reports new photophobia and “bright halos around lights” since yesterday
- Day 2: Brief blurred vision after first IV dose—documented as transient; no prescriber call
- Day 6: Switched to oral after tolerating diet; oral suspension shaken per protocol
- 0800: Patient refused sunscreen teaching; wants to sit by sunny window
- 1100: Pharmacy note—phenytoin may reduce voriconazole levels; maintenance dose not yet adjusted
Answer key & rationale
Frequently asked questions
What should nurses check before giving voriconazole?
Review azole allergy history, weight for IV dosing, baseline and recent liver function tests, creatinine clearance (route selection), potassium/magnesium/calcium, concurrent QT-prolonging or contraindicated drugs (rifampin, sirolimus, pimozide, ergot alkalines), pregnancy status, and whether loading doses were completed. Verify oral suspension is shaken and oral doses are scheduled 1 hour before or after meals.
When should a nurse hold voriconazole?
Hold for hypersensitivity or infusion-related anaphylactoid symptoms (stop IV immediately), markedly elevated liver enzymes compared with baseline, clinical hepatitis or jaundice, persistent or worsening visual changes especially beyond 28 days, severe cutaneous reactions, and IV orders when creatinine clearance is below 50 mL/min without prescriber-documented benefit/risk justification. Clarify maintenance dose when phenytoin or efavirenz is added because labeling requires voriconazole dose adjustment.
Why do visual changes matter with voriconazole?
Visual disturbances occurred in about 19% of adults in clinical trials and are a hallmark adverse effect. Most early changes are transient, but labeling warns of prolonged visual adverse reactions including optic neuritis and papilledema with longer therapy. Nurses should document symptoms, teach patients not to drive at night if vision is affected, and escalate persistent symptoms for ophthalmology and prescriber review.
Can voriconazole be given IV if the patient has renal impairment?
Avoid IV voriconazole in moderate to severe renal impairment (creatinine clearance less than 50 mL/min) because the IV vehicle SBECD accumulates. Oral voriconazole does not require the same renal dose adjustment per labeling, though creatinine should still be monitored. Use IV only if prescriber documents that benefit outweighs risk.
Is voriconazole safe in pregnancy and breastfeeding?
Voriconazole can cause fetal harm per prescribing information; there are no adequate human pregnancy data. Animal studies showed malformations and fetal toxicity. Effective contraception is advised during treatment. No human lactation data are available—breastfeeding decisions should weigh maternal clinical need against potential infant exposure per prescriber counseling.
References
-
U.S. National Library of Medicine. VFEND (voriconazole) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce3ef5cf-3087-4d92-9d94-9eb8287228db
-
Patterson TF, et al. Infectious Diseases Society of America. Clinical Practice Guideline for the Diagnosis and Management of Aspergillosis: 2016 Update.https://www.idsociety.org/practice-guideline/aspergillosis/
-
Pappas PG, et al. Infectious Diseases Society of America. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update.https://www.idsociety.org/practice-guideline/candidiasis/
-
Drugs and Lactation Database (LactMed). Voriconazole. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501922/
-
Pfizer Inc. VFEND (voriconazole) prescribing information. FDA label repository.https://labeling.pfizer.com/showlabeling.aspx?id=618
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.